XML 60 R49.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Segment Reporting (Details) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2022 USD ($) business | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) reportablesegments business | Sep. 30, 2021 USD ($)
Segment Reporting [Abstract] |  |  |  |
Number Of Businesses | business | 5 |  | 5 |
Number of reportable segments | reportablesegments |  |  | 2 |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Amortization expense | $ (202) | $ (184) | $ (604) | $ (549)
Operating income (loss) | 358 | 387 | 1,247 | 1,019
Other expense, net | (114) | 95 | (502) | (62)
Income (loss) before income taxes | 245 | 483 | 745 | 957
Impact of Foreign Currency Fluctuations on Net Sales | (155) | 8 | (294) | 65
Net sales | 3,170 | 2,932 | 9,440 | 8,761
United States |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 1,934 | 1,726 | 5,645 | 5,112
International [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 1,236 | 1,206 | 3,795 | 3,649
Endoscopy [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 559 | 533 | 1,649 | 1,583
Endoscopy [Member] | United States |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 342 | 306 | 992 | 902
Endoscopy [Member] | International [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 217 | 227 | 657 | 681
Urology and Pelvic Health [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 433 | 384 | 1,296 | 1,142
Urology and Pelvic Health [Member] | United States |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 315 | 275 | 921 | 817
Urology and Pelvic Health [Member] | International [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 118 | 109 | 375 | 325
Neuromodulation [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 221 | 221 | 669 | 666
Neuromodulation [Member] | United States |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 173 | 175 | 519 | 520
Neuromodulation [Member] | International [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 48 | 46 | 150 | 145
Interventional Cardiology Therapies |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 549 | 534 | 1,667 | 1,634
Interventional Cardiology Therapies | United States |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 190 | 193 | 568 | 593
Interventional Cardiology Therapies | International [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 359 | 341 | 1,099 | 1,041
Watchman |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 262 | 210 | 738 | 596
Watchman | United States |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 234 | 183 | 662 | 524
Watchman | International [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 28 | 26 | 76 | 72
Cardiac Rhythm Management [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 519 | 512 | 1,580 | 1,505
Cardiac Rhythm Management [Member] | United States |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 338 | 312 | 1,005 | 903
Cardiac Rhythm Management [Member] | International [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 181 | 199 | 575 | 603
Electrophysiology [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 148 | 86 | 418 | 265
Electrophysiology [Member] | United States |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 73 | 32 | 196 | 96
Electrophysiology [Member] | International [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 75 | 55 | 222 | 169
Cardiology [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 1,479 | 1,342 | 4,403 | 4,000
Cardiology [Member] | United States |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 836 | 720 | 2,431 | 2,115
Cardiology [Member] | International [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 643 | 622 | 1,972 | 1,885
Peripheral Interventions [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 479 | 452 | 1,423 | 1,358
Peripheral Interventions [Member] | United States |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 269 | 250 | 782 | 748
Peripheral Interventions [Member] | International [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 210 | 202 | 641 | 609
Specialty Pharmaceuticals [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Revenues from contracts with customers, disaggregated - performance measurement | 0 | 0 | 0 | 13
Net sales | 0 | 0 | 0 | 13
Specialty Pharmaceuticals [Member] | United States |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 0 | 0 | 0 | 10
Specialty Pharmaceuticals [Member] | International [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 0 | 0 | 0 | 4
MedSurg [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Operating Income Allocated to Reportable Segments | 399 | 370 | 1,168 | 1,117
Revenues from contracts with customers, disaggregated - performance measurement | $ 1,260 | $ 1,135 | $ 3,702 | $ 3,368
Segment operating income as percentage of net sales | 31.70% | 32.60% | 31.60% | 33.20%
Net sales | $ 1,213 | $ 1,138 | $ 3,614 | $ 3,390
MedSurg [Member] | United States |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 830 | 756 | 2,432 | 2,239
MedSurg [Member] | International [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 383 | 382 | 1,182 | 1,151
Cardiovascular [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Operating Income Allocated to Reportable Segments | 542 | 479 | 1,562 | 1,468
Revenues from contracts with customers, disaggregated - performance measurement | $ 2,065 | $ 1,789 | $ 6,032 | $ 5,315
Segment operating income as percentage of net sales | 26.30% | 26.80% | 25.90% | 27.60%
Net sales | $ 1,958 | $ 1,794 | $ 5,826 | $ 5,358
Cardiovascular [Member] | United States |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 1,104 | 970 | 3,213 | 2,864
Cardiovascular [Member] | International [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 853 | 824 | 2,613 | 2,494
BSX Reportable Segments [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Revenues from contracts with customers, disaggregated - performance measurement | 3,325 | 2,924 | 9,734 | 8,683
Net sales | 3,170 | 2,932 | 9,440 | 8,748
BSX Reportable Segments [Member] | United States |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Net sales | 1,934 | 1,726 | 5,645 | 5,103
Total allocated to reportable segments [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Operating income (loss) | 942 | 849 | 2,730 | 2,585
Specialty Pharmaceuticals [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Operating income (loss) | 0 | 0 | 0 | 4
Corporate expenses and currency exchange [Member] |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Operating Income Unallocated to Segment | (132) | (99) | (321) | (397)
Intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits |  |  |  |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] |  |  |  |
Operating Income Unallocated to Segment | $ (249) | $ (178) | $ (558) | $ (624)

X
- Definition Impact of Foreign Currency Fluctuations on Net Sales + References No definition available. + Details
Name: | bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales
Namespace Prefix: | bsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number Of Businesses + References No definition available. + Details
Name: | bsx_NumberOfBusinesses
Namespace Prefix: | bsx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Operating Income Allocated to Reportable Segments + References No definition available. + Details
Name: | bsx_OperatingIncomeAllocatedToReportableSegments
Namespace Prefix: | bsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Operating Income Unallocated to Segment + References No definition available. + Details
Name: | bsx_OperatingIncomeUnallocatedToSegment
Namespace Prefix: | bsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenues from contracts with customers, disaggregated - performance measurement - measures used by CODM to make business decisions, excludes impact of foreign currency fluctuations + References No definition available. + Details
Name: | bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement
Namespace Prefix: | bsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Segment operating income as percentage of net sales + References No definition available. + Details
Name: | bsx_Segmentoperatingincomeaspercentageofnetsales
Namespace Prefix: | bsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 940 -SubTopic 20 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(8)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 + Details
Name: | us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_NonoperatingIncomeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599 + Details
Name: | us-gaap_NumberOfReportableSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The net result for the period of deducting operating expenses from operating revenues. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 + Details
Name: | us-gaap_OperatingIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalEndoscopyEndoReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalUrologyandPelvicHealthReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalNeuromodulationNmReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_InterventionalCardiologyTherapiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_WatchmanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_CardiacRhythmManagementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_ElectrophysiologyEPMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalCardiologyReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalPeripheralInterventionsPiReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_SpecialtyPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bsx_MedsurgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bsx_CardiovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bsx_BSXReportableSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bsx_TotalAllocatedToReportableSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bsx_SpecialtyPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bsx_CorporateExpensesincludinghedgingactivitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bsx_SpecialChargesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |